GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
This invention provides tablets comprising gemcabene calcium salt hydrate Crystal Form 2 or gemcabene calcium salt hydrate Crystal Form C3, each having a PSD90 ranging from 35 μm to 90 μm as measured by laser light diffraction and wherein the tablet has a gemcabene dissolution profile characterized...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French German |
Published |
25.08.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This invention provides tablets comprising gemcabene calcium salt hydrate Crystal Form 2 or gemcabene calcium salt hydrate Crystal Form C3, each having a PSD90 ranging from 35 μm to 90 μm as measured by laser light diffraction and wherein the tablet has a gemcabene dissolution profile characterized by a % dissolution profile of at least 80% in pH 5.0 potassium acetate buffer at 37° C.±0.5° C. in no more than 45 minutes as measured by ultra-violet/visible light absorption using a detection wavelength range of 216 nm to 230 nm. This invention further provides gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6. The tablets and gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6 are useful for treating or preventing liver disease or an abnormal liver condition, a disorder of lipoprotein or glucose metabolism, a cardiovascular or related vascular disorder, a disease caused by fibrosis (such as liver fibrosis), or a disease associated with inflammation (such as liver inflammation). |
---|---|
AbstractList | This invention provides tablets comprising gemcabene calcium salt hydrate Crystal Form 2 or gemcabene calcium salt hydrate Crystal Form C3, each having a PSD90 ranging from 35 μm to 90 μm as measured by laser light diffraction and wherein the tablet has a gemcabene dissolution profile characterized by a % dissolution profile of at least 80% in pH 5.0 potassium acetate buffer at 37° C.±0.5° C. in no more than 45 minutes as measured by ultra-violet/visible light absorption using a detection wavelength range of 216 nm to 230 nm. This invention further provides gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6. The tablets and gemcabene calcium salt hydrate Crystal Forms 4, 5 and 6 are useful for treating or preventing liver disease or an abnormal liver condition, a disorder of lipoprotein or glucose metabolism, a cardiovascular or related vascular disorder, a disease caused by fibrosis (such as liver fibrosis), or a disease associated with inflammation (such as liver inflammation). |
Author | GREENE, Matthew Benjamin ONICIU, Daniela Carmen BISGAIER, Charles Larry |
Author_xml | – fullname: GREENE, Matthew Benjamin – fullname: BISGAIER, Charles Larry – fullname: ONICIU, Daniela Carmen |
BookMark | eNqNirsOgkAQRbfQwtc_zAdgISZqOwyDS7LLbtihsCLELJUBEvz_aKKxtro559y1WgzjEFeqv7IlzLjiBLzG2iJxIyWhMTdAIvaCmWEIaCSAaK7ZFQmQs96FUkpX_SxglYNl0S4P8MYm8CcVrt6qZd895rj77kZBwUJ6H6exjfPU3eMQny374-V0TtMUD8c_Li-UPjZa |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | GEMCABEN, PHARMAZEUTISCH UNBEDENKLICHE SALZE DAVON, ZUSAMMENSETZUNGEN DAVON UND VERFAHREN ZUR VERWENDUNG DAVON GEMCABÈNE, SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI, COMPOSITIONS CORRESPONDANTES ET PROCÉDÉS D'UTILISATION ASSOCIÉS |
ExternalDocumentID | EP3867222A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_EP3867222A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 15:14:29 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French German |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_EP3867222A13 |
Notes | Application Number: EP20190872419 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210825&DB=EPODOC&CC=EP&NR=3867222A1 |
ParticipantIDs | epo_espacenet_EP3867222A1 |
PublicationCentury | 2000 |
PublicationDate | 20210825 |
PublicationDateYYYYMMDD | 2021-08-25 |
PublicationDate_xml | – month: 08 year: 2021 text: 20210825 day: 25 |
PublicationDecade | 2020 |
PublicationYear | 2021 |
RelatedCompanies | Gemphire Therapeutics Inc |
RelatedCompanies_xml | – name: Gemphire Therapeutics Inc |
Score | 3.3477688 |
Snippet | This invention provides tablets comprising gemcabene calcium salt hydrate Crystal Form 2 or gemcabene calcium salt hydrate Crystal Form C3, each having a PSD90... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY METALLURGY ORGANIC CHEMISTRY |
Title | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210825&DB=EPODOC&locale=&CC=EP&NR=3867222A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT8IwFH8haNSbokb8Sg9mJxYZYxs7ENN1ndOwj7Bi8GQY2xIug8iM_76vE9CLntq-Jk37kl9ff699rwB3htXrZzO7q_ZnM11FJBaqbWaamtnIndNCK-apdA0EoelP-s9TY9qAxTYWps4T-lknR0REzRHvVb1fr36cWG79tnJ9ny5QtHzwxNBVNuwY-QsyHsV1hjyO3IgpjGFNCcdDfWBaaAopEqU9PEVbEgz8xZFBKavfFsU7hv0YByurE2jkZQsO2fbjtRYcBJv7bqxuoLc-heKRB4w6POQdEvt0HFDGJ0JmMxi9EsoYjwV1RpwkdCQSInw-5pHXISwK4ih5qoOFt1JCQ5cEXPiRmxBsThL-3YWM8AyIxwXzVZzw2045bzzeLU0_h2a5LPMLIKh4W8t7llnggUiz8oFhyLzvuizsbjdrQ_vPYS7_6buCI6ll6VTtGdfQrN4_8hu0ylV6W-vzCwKMh94 |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT8IwFG8IGvGmqBH86sHsxCJjbGMHYrquc-i-worBE2FsS7gMIjP--75OQC96avuaNO1Lfn39vfa9InSvGb1-Oje7cn8-V2VAYi6beqrIqQncOcmVfJEI14Af6O6k_zzVpjW03MXCVHlCP6vkiICoBeC9rPbr9Y8Ty67eVm4ekiWIVo8OH9rSlh0DfwHGI9nWkEWhHVKJUqhJwXioDnQDTCEBonQAJ2xDgIG9WiIoZf3bojgn6DCCwYryFNWyookadPfxWhMd-dv7bqhuobc5Q_kT8ymxWMA6OHLJ2CeUTbjIZuC9YUIpizixPIZj4vEYc5eNWeh0MA39KIxHVbDwTopJYGOfcTe0YwzNScy-u4ARniPsME5dGSY82ytnxqL90tQLVC9WRXaJMCjeVLKeoedwIFKMbKBpIu-7Kgqz201bqPXnMO1_-u5Qw-W-N_NGwcsVOhYaFw7WnnaN6uX7R3YDFrpMbivdfgGOfIrR |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=GEMCABENE%2C+PHARMACEUTICALLY+ACCEPTABLE+SALTS+THEREOF%2C+COMPOSITIONS+THEREOF+AND+METHODS+OF+USE+THEREFOR&rft.inventor=GREENE%2C+Matthew+Benjamin&rft.inventor=BISGAIER%2C+Charles+Larry&rft.inventor=ONICIU%2C+Daniela+Carmen&rft.date=2021-08-25&rft.externalDBID=A1&rft.externalDocID=EP3867222A1 |